Eli Lilly and PE ratio LLY

Share price divided by earnings per share over the last twelve months, since 1997.

Today, Oct 23, 2026: 42.7×
10-year median: 41.4×
Against its 10-year history: 52nd; percentile: 0 is its lowest day, 100 its highest
10-year range: 13.4× to 278×
Peer median: 39.7×

Eli Lilly and's PE ratio is 42.7× as of Oct 23, 2026: a share price of $1,273.46 against $29.80 of earnings per share over the last twelve months.

That is above its ten-year median of 41.4×, close to the middle of its last ten years.

Over that time it ranged from 13.4× in Oct 2019 to 278× in Feb 2019.

The median for 7 large drugmakers of a similar size is 39.7×.

PE ratio over time

median 41.4×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	42.7×	33.7×	52.9×
2025	52.7×	40.9×	87.7×
2024	84.7×	80.7×	142×
2023	106×	45.7×	109×
2022	54.9×	35.9×	57.4×
2021	42.1×	27.1×	42.1×
2020	27.6×	14.0×	28.1×
2019	16.0×	13.4×	278×
2018	260×	36.1×	270×
2017	40.0×	31.7×	41.0×
2016	32.0×	29.4×	37.6×
2015	38.1×	28.0×	45.8×
2014	28.2×	11.7×	29.0×
2013	11.7×	10.9×	15.7×
2012	13.2×	9.3×	14.6×
2011	9.9×	7.4×	10.0×
2010	8.0×	7.8×	9.3×
2009	n/m a value too high to mean anything
2008	17.4×	16.8×	27.7×
2007	26.4×	24.8×	29.7×

Against its peers

Companies in Drug Manufacturers - General nearest Eli Lilly and's size, closest first, today.

Company	PE ratio
LLYEli Lilly and	42.7×
JNJJohnson & Johnson	40.0×
ABBVAbbVie	80.7×
MRKMerck	116×
AMGNAmgen	27.3×
GILDGilead Sciences	n/m
PFEPfizer	39.5×
BMYBristol-Myers Squibb	13.5×
Peer median	39.7×

Where Eli Lilly and ranks

#30of 41Large drugmakers with the lowest PE ratio

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Eli Lilly and

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.